Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04855773 · ClinicalTrials.gov registry record · NA

Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

A NA study of HIV Infections and Sexually Transmitted Diseases, sponsored by Public Health Foundation Enterprises.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
4
Study locations

NCT04855773: Recruiting NA study of HIV Infections and Sexually Transmitted Diseases, sponsored by Public Health Foundation Enterprises.

NCT04855773 is a NA study of HIV Infections and Sexually Transmitted Diseases that is actively recruiting participants, run by Public Health Foundation Enterprises. The registered enrollment target is 300 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04855773, a NA study of HIV Infections and Sexually Transmitted Diseases, is actively recruiting participants, sponsored by Public Health Foundation Enterprises.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help prevent HIV infection.

Primary Outcome

PrEP adherence will be measured by tenofovir diphosphate (TFV-DP) levels in dried blood spots (DBS). Adequate adherence will be defined as having a TFV-DP ≥ 700 femtomoles/punch in DBS for daily PrEP users, which has been associated with high levels of protection in prior PrEP trials.

Interventions

  • OTHER PrEPmate
  • DEVICE Dot Diary

Study Locations (4)

California

  • Bridge HIV, San Francisco Department of Public Health - San Francisco
  • San Francisco AIDS Foundation - San Francisco

District of Columbia

  • Whitman-Walker Health - Washington D.C.

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2021-07-21
Est. Completion 2023-08
Phase NA

What NCT04855773 shows while recruiting

NCT04855773 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (33% lower).

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which PrEPmate is the first listed.

NCT04855773 reports a single indexed study location in California, District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT04855773 about?

NCT04855773 is a clinical study titled "Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention". The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help prev...

What is the current status of trial NCT04855773?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2021-07-21. Estimated completion is 2023-08.

What conditions does trial NCT04855773 study?

This clinical trial studies the following conditions: HIV Infections, Sexually Transmitted Diseases.

What interventions are being tested in trial NCT04855773?

The interventions under investigation include: PrEPmate (OTHER), Dot Diary (DEVICE).

Who is sponsoring clinical trial NCT04855773?

This trial is sponsored by Public Health Foundation Enterprises, which has 11 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04855773 being conducted?

This trial has 4 study locations across California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04855773's enrollment target sits among peer trials

300 115th of 542 higher than 417 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04855773, the US trial registry maintained by the National Library of Medicine. NCT04855773 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.